横紋筋肉腫患者の全国調査によって我が国の治療成績が判明
Hosoi H, Teramukai S, Matsumoto Y, Tsuchiya K, Iehara T, Hara J, Mitsui T, Kaneko M, Hatae Y, Hayashi Y, Mabuchi O, Adachi N, Morikawa Y, Nishimura S, Kumagai M, Takamatsu H, Sawada T, Sugimoto T. A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol. 12 (2): 137-145,2007.
神経芽腫患者登録の解析から我が国のマス・スクリーニングの死亡率の低下を証明
Hiyama E, Iehara T, Sugimoto T, Fukuzawa M, Hayashi Y, Sasaki F, Sugiyama M, Kondo S, Yoneda A, Yamaoka H, Tajiri T, Akazawa K, Ohtaki M.Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet. Apr 5;371(9619): 1173-1180,2008.
神経芽腫患者登録の解析から乳児期の予後不良例MYCN増幅例を証明
Iehara T, Hosoi H, Akazawa K, Matsumoto Y, Yamamoto K, Suita S, Tajiri T, Kusafuka T, Hiyama E, Kaneko M, Sasaki F, Sugimoto T, Sawada T. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer. 94(10): 1510-1515,2006.
神経芽腫患者登録の解析から乳児期以降の病期4sも予後良好であることを証明
Iehara T, Hiyama E, Tajiri T, Yoneda A, Hamazaki M, Fukuzawa M, Hosoi H, Sugimoto T, Sawada T. Is the prognosis of stage 4s neuroblastoma in patients 12months of age and older really excellent? Eur J Cancer Feb 1. 2012.
